Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application


Benzinga | Aug 2, 2021 08:03AM EDT

Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application

* Protalix BioTherapeutics Inc (NYSE:PLX) has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April.

* The FDA issued the response letter for pegunigalsidase alfa (PRX-102) in Fabry disease, though no reasons were cited in the letter.

* The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.

* Price Action: PLX shares are up 4.63% at $1.58 during the premarket session on the last check Monday.

* Related content: Benzinga's Full FDA Calendar.







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC